Low glucose promotes CD133mAb-elicited cell death via inhibition of autophagy in hepatocarcinoma cells

Cancer Letters

Volumn 336, Issue 1, 2013, Pages 204-212

  Chen, Haiyang ^a   Luo, Zaili ^a   Sun, Wen ^a   Zhang, Cunzhen ^a   Sun, Huanlin ^a   Zhao, Nanjie ^a   Ding, Jin ^a   Wu, Mengchao ^a   Li, Zhong ^a   Wang, Hongyang ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Antibody; Cancer stem cells; CD133; Cell death; Hepatocellular carcinoma

Indexed keywords

AC 133; ANTINEOPLASTIC AGENT; CD133 ANTIBODY; CD133 ANTIGEN; CISPLATIN; DOXORUBICIN; GLUCOSE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOPHAGY; CANCER INHIBITION; CARCINOMA CELL; CELL DEATH; CELL STRAIN HEPG2; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG TARGETING; HUMAN; HUMAN CELL; LIVER CELL; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; PRIMARY CELL CULTURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR SPHEROID; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; APOPTOSIS; AUTOPHAGY; CARCINOMA, HEPATOCELLULAR; CELL COUNT; CELL DEATH; CELL LINE, TUMOR; COLLAGEN; DRUG COMBINATIONS; GLUCOSE; GLYCOPROTEINS; HEPATOCYTES; HUMANS; LAMININ; LIVER NEOPLASMS; MALE; MICE; MICE, NUDE; NECROSIS; NEOPLASM TRANSPLANTATION; PEPTIDES; PROTEOGLYCANS;

EID: 84878956256     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.04.031     Document Type: Article

References (53)

1. Yao Z., Mishra L. Cancer stem cells and hepatocellular carcinoma. Cancer Biol. Ther. 2009, 8:1691-1698.
2. Tong C.M., Ma S., Guan X.Y. Biology of hepatic cancer stem cells. J. Gastroenterol. Hepatol. 2011, 26:1229-1237.
3. Gish R.G. Hepatocellular carcinoma: overcoming challenges in disease management. Clin. Gastroenterol. Hepatol. 2006, 4:252-261.
4. Chiba T., Kamiya A., Yokosuka O., Iwama A. Cancer stem cells in hepatocellular carcinoma: recent progress and perspective. Cancer Lett. 2009, 286:145-153.
5. Ma S. Biology and clinical implications of CD133(+) liver cancer stem cells. Exp. Cell Res. 2013, 319:126-132.
6. Miraglia S., Godfrey W., Yin A.H., Atkins K., Warnke R., Holden J.T., Bray R.A., Waller E.K., Buck D.W. A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood 1997, 90:5013-5021.
7. Yin A.H., Miraglia S., Zanjani E.D., Almeida-Porada G., Ogawa M., Leary A.G., Olweus J., Kearney J., Buck D.W. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 1997, 90:5002-5012.
8. Wu Y., Wu P.Y. CD133 as a marker for cancer stem cells: progresses and concerns. Stem Cells Dev. 2009, 18:1127-1134.
9. Missol-Kolka E., Karbanova J., Janich P., Haase M., Fargeas C.A., Huttner W.B., Corbeil D. Prominin-1 (CD133) is not restricted to stem cells located in the basal compartment of murine and human prostate. Prostate 2011, 71:254-267.
10. Corbeil D., Roper K., Fargeas C.A., Joester A., Huttner W.B. Prominin: a story of cholesterol, plasma membrane protrusions and human pathology. Traffic 2001, 2:82-91.
11. Lardon J., Corbeil D., Huttner W.B., Ling Z., Bouwens L. Stem cell marker prominin-1/AC133 is expressed in duct cells of the adult human pancreas. Pancreas 2008, 36:e1-6.
12. Sasaki A., Kamiyama T., Yokoo H., Nakanishi K., Kubota K., Haga H., Matsushita M., Ozaki M., Matsuno Y., Todo S. Cytoplasmic expression of CD133 is an important risk factor for overall survival in hepatocellular carcinoma. Oncol. Rep. 2010, 24:537-546.
13. Rappa G., Fodstad O., Lorico A. The stem cell-associated antigen CD133 (Prominin-1) is a molecular therapeutic target for metastatic melanoma. Stem Cells 2008, 26:3008-3017.
14. Smith L.M., Nesterova A., Ryan M.C., Duniho S., Jonas M., Anderson M., Zabinski R.F., Sutherland M.K., Gerber H.P., Van Orden K.L., Moore P.A., Ruben S.M., Carter P.J. CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers. Br. J. Cancer 2008, 99:100-109.
15. Chen W., Li F., Xue Z.M., Wu H.R. Anti-human CD133 monoclonal antibody that could inhibit the proliferation of colorectal cancer cells. Hybridoma (Larchmt) 2010, 29:305-310.
16. Damek-Poprawa M., Volgina A., Korostoff J., Sollecito T.P., Brose M.S., O'Malley B.W., Akintoye S.O., DiRienzo J.M. Targeted inhibition of CD133+ cells in oral cancer cell lines. J Dent Res 2011, 90:638-645.
17. Ma S., Lee T.K., Zheng B.J., Chan K.W., Guan X.Y. CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene 2008, 27:1749-1758.
18. Dong L., Qi N., Ge R.M., Cao C.L., Lan F., Shen L. Overexpression of CD133 promotes the phosphorylation of Erk in U87MG human glioblastoma cells. Neurosci. Lett. 2010, 484:210-214.
19. Bourseau-Guilmain E., Griveau A., Benoit J.P., Garcion E. The importance of the stem cell marker prominin-1/CD133 in the uptake of transferrin and in iron metabolism in human colon cancer Caco-2 cells. PLoS ONE 2011, 6:e25515.
20. Kohga K., Tatsumi T., Takehara T., Tsunematsu H., Shimizu S., Yamamoto M., Sasakawa A., Miyagi T., Hayashi N. Expression of CD133 confers malignant potential by regulating metalloproteinases in human hepatocellular carcinoma. J. Hepatol. 2010, 52:872-879.
21. Tang K.H., Ma S., Lee T.K., Chan Y.P., Kwan P.S., Tong C.M., Ng I.O., Man K., To K.F., Lai P.B., Lo C.M., Guan X.Y., Chan K.W. CD133(+) liver tumor-initiating cells promote tumor angiogenesis, growth, and self-renewal through neurotensin/interleukin-8/CXCL1 signaling. Hepatology 2012, 55:807-820.
22. Griguer C.E., Oliva C.R., Gobin E., Marcorelles P., Benos D.J., Lancaster J.R., Gillespie G.Y. CD133 is a marker of bioenergetic stress in human glioma. PLoS ONE 2008, 3:e3655.
23. Nikolova T., Wu M., Brumbarov K., Alt R., Opitz H., Boheler K.R., Cross M., Wobus A.M. WNT-conditioned media differentially affect the proliferation and differentiation of cord blood-derived CD133+ cells in vitro. Differentiation 2007, 75:100-111.
24. Chen H., Luo Z., Dong L., Tan Y., Yang J., Feng G., Wu M., Li Z., Wang H. CD133/prominin-1-mediated autophagy and glucose uptake beneficial for hepatoma cell survival. PLoS ONE 2013, 8:e56878.
25. Wang C., Yang W., Yan H.X., Luo T., Zhang J., Tang L., Wu F.Q., Zhang H.L., Yu L.X., Zheng L.Y., Li Y.Q., Dong W., He Y.Q., Liu Q., Zou S.S., Lin Y., Hu L., Li Z., Wu M.C., Wang H.Y. Hepatitis B virus X (HBx) induces tumorigenicity of hepatic progenitor cells in 3,5-diethoxycarbonyl-1,4-dihydrocollidine-treated HBx transgenic mice. Hepatology 2012, 55:108-120.
26. Zhu Z., Hao X., Yan M., Yao M., Ge C., Gu J., Li J. Cancer stem/progenitor cells are highly enriched in CD133+CD44+ population in hepatocellular carcinoma. Int. J. Cancer 2010, 126:2067-2078.
27. Wang B., Jacob S.T. Role of cancer stem cells in hepatocarcinogenesis. Genome Med 2011, 3:11.
28. Fargeas C.A., Karbanova J., Jaszai J., Corbeil D. CD133 and membrane microdomains: old facets for future hypotheses. World J. Gastroenterol. 2011, 17:4149-4152.
29. El Mjiyad N., Caro-Maldonado A., Ramirez-Peinado S., Munoz-Pinedo C. Sugar-free approaches to cancer cell killing. Oncogene 2011, 30:253-264.
30. Canis M., Lechner A., Mack B., Zengel P., Laubender R.P., Koehler U., Heissmeyer V., Gires O. CD133 induces tumour-initiating properties in HEK293 cells. Tumour Biol. 2013, 34:437-443.
31. Hou Y., Zou Q., Ge R., Shen F., Wang Y. The critical role of CD133(+)CD44(+/high) tumor cells in hematogenous metastasis of liver cancers. Cell Res. 2012, 22:259-272.
32. Deonarain M.P., Kousparou C.A., Epenetos A.A. Antibodies targeting cancer stem cells: a new paradigm in immunotherapy?. MAbs 2009, 1:12-25.
33. Mano M., Humblet Y. Drug Insight: panitumumab, a human EGFR-targeted monoclonal antibody with promising clinical activity in colorectal cancer. Nat. Clin. Pract. Oncol. 2008, 5:415-425.
34. Woo H.Y., Heo J. Sorafenib in liver cancer. Expert Opin. Pharmacother. 2012, 13:1059-1067.
35. Kurtz J.E., Dufour P. Adecatumumab: an anti-EpCAM monoclonal antibody, from the bench to the bedside. Expert Opin. Biol. Ther. 2010, 10:951-958.
36. Yin S., Li J., Hu C., Chen X., Yao M., Yan M., Jiang G., Ge C., Xie H., Wan D., Yang S., Zheng S., Gu J. CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int. J. Cancer 2007, 120:1444-1450.
37. Suetsugu A., Nagaki M., Aoki H., Motohashi T., Kunisada T., Moriwaki H. Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem. Biophys. Res. Commun. 2006, 351:820-824.
38. Yan L., Ehrlich P.J., Gibson R., Pickett C., Beckman R.A. How can we improve antibody-based cancer therapy?. MAbs 2009, 1:67-70.
39. O'Mahony D., Bishop M.R. Monoclonal antibody therapy. Front. Biosci. 2006, 11:1620-1635.
40. Ma S., Tang K.H., Chan Y.P., Lee T.K., Kwan P.S., Castilho A., Ng I., Man K., Wong N., To K.F., Zheng B.J., Lai P.B., Lo C.M., Chan K.W., Guan X.Y. MiR-130b Promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1. Cell Stem Cell 2010, 7:694-707.
41. Roper K., Corbeil D., Huttner W.B. Retention of prominin in microvilli reveals distinct cholesterol-based lipid micro-domains in the apical plasma membrane. Nat. Cell Biol. 2000, 2:582-592.
42. Marzesco A.M., Janich P., Wilsch-Brauninger M., Dubreuil V., Langenfeld K., Corbeil D., Huttner W.B. Release of extracellular membrane particles carrying the stem cell marker prominin-1 (CD133) from neural progenitors and other epithelial cells. J. Cell Sci. 2005, 118:2849-2858.
43. Bauer N., Wilsch-Brauninger M., Karbanova J., Fonseca A.V., Strauss D., Freund D., Thiele C., Huttner W.B., Bornhauser M., Corbeil D. Haematopoietic stem cell differentiation promotes the release of prominin-1/CD133-containing membrane vesicles-a role of the endocytic-exocytic pathway. EMBO Mol Med 2011, 3:398-409.
44. Zacchigna S., Oh H., Wilsch-Brauninger M., Missol-Kolka E., Jaszai J., Jansen S., Tanimoto N., Tonagel F., Seeliger M., Huttner W.B., Corbeil D., Dewerchin M., Vinckier S., Moons L., Carmeliet P. Loss of the cholesterol-binding protein prominin-1/CD133 causes disk dysmorphogenesis and photoreceptor degeneration. J. Neurosci. 2009, 29:2297-2308.
45. Damek-Poprawa M., Volgina A., Korostoff J., Sollecito T.P., Brose M.S., O'Malley B.W., Akintoye S.O., DiRienzo J.M. Targeted inhibition of CD133+ cells in oral cancer cell lines. J. Dent. Res. 2011, 90:638-645.
46. Bussolati B., Collino F., Camussi G. CD133+ cells as a therapeutic target for kidney diseases. Expert Opin. Ther. Targets 2012, 16:157-165.
47. Lan X., Wu Y.Z., Wang Y., Wu F.R., Zang C.B., Tang C., Cao S., Li S.L. CD133 silencing inhibits stemness properties and enhances chemoradiosensitivity in CD133-positive liver cancer stem cells. Int. J. Mol. Med. 2013, 31:315-324.
48. Moreno-Sanchez R., Saavedra E., Rodriguez-Enriquez S., Gallardo-Perez J.C., Quezada H., Westerhoff H.V. Metabolic control analysis indicates a change of strategy in the treatment of cancer. Mitochondrion 2010, 10:626-639.
49. Zhao Y., Liu H., Liu Z., Ding Y., Ledoux S.P., Wilson G.L., Voellmy R., Lin Y., Lin W., Nahta R., Liu B., Fodstad O., Chen J., Wu Y., Price J.E., Tan M. Overcoming trastuzumab resistance in breast cancer by targeting dysregulated glucose metabolism. Cancer Res. 2011, 71:4585-4597.
50. Zeng L., Biernacka K.M., Holly J.M., Jarrett C., Morrison A.A., Morgan A., Winters Z.E., Foulstone E.J., Shield J.P., Perks C.M. Hyperglycaemia confers resistance to chemotherapy on breast cancer cells: the role of fatty acid synthase. Endocr. Relat. Cancer 2010, 17:539-551.
51. Rocha G.Z., Dias M.M., Ropelle E.R., Osorio-Costa F., Rossato F.A., Vercesi A.E., Saad M.J., Carvalheira J.B. Metformin amplifies chemotherapy-induced AMPK activation and antitumoral growth. Clin. Cancer Res. 2011, 17:3993-4005.
52. Iliopoulos D., Hirsch H.A., Struhl K. Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types. Cancer Res. 2011, 71:3196-3201.
53. Hirsch H.A., Iliopoulos D., Tsichlis P.N., Struhl K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res. 2009, 69:7507-7511.